A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing ...

The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...

A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

TCG Labs Soleil has secured $400 million to boost the firm’s ability to advance its biotech portfolio companies while also ...

The orthopedic implant maker Shoulder Innovations is the latest medtech to plan for a nine-figure IPO, as it looks to scale ...

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger.

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...